ADC in oncology

Jun 12, 2026

Pfizer's USD 10.5 billion partnership with Innovent Biologics is not just another oncology deal; it is a strategic masterstroke in Pfizer's bid to dominate cancer therapy. In May 2026, Pfizer and Innovent announced a global collaboration covering 12 early-stage and de novo oncology programs, including next-generati...

Apr 15, 2024

ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous sy...

Jun 02, 2023

Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the...